Kadcyla : Armed antibody is a comprehensive report on the first USFDA approved drug with antibody-drug conjugate for HER2-positive metastatic breast cancer treatment. Kadcyla falls in the monoclonal antibody, HER 2-targeted antibody-drug conjugate, class of drugs belonging to the targeted therapy.